The advances in understanding the role of PI3K/AKT/mTOR axis in these malformations have opened the era of exploiting targeted therapies, as summarized in Table 2, which highlights current and upcoming clinical trials on PI3K axis inhibitors for vascular malformations. This evidence concerns the gene PIK3CB and vascular malformation.